Participants
Contact
The Innovadores supplement of today’s El Mundo reports on the funding that Ernest Giralt’s group has received from Genefa, the association of patients with Friedreich's ataxia, to study this rare disease. The report explains how patients and scientists have come together to undertake a new scientific project.
The project is a collaboration between the Center for Molecular Biology Severo Ochoa in Madrid (CMBSO) and IRB, which unites Ernest Giralt’s (IRB) work on brain shuttle drug transporters and Javier Diaz-Nido’s studies on gene therapy treatment for Friedreich’s ataxia.
This kind of collaboration between researchers and patients’ associations achieves a much closer relationship between the two groups, which often have little chance for interaction.
El Mundo, Innovadores supplement (PDF in Spanish)
Related News
28 January 2014
International patient advocates partner to fund Spanish gene-therapy project to treat Friedreich's ataxia
14 November 2013
Patients and scientists join forces to tackle Friedreich’s Ataxia
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
